脑蛋白水解物联合多巴丝肼治疗帕金森病患者的效果

Effects of Cerebroprotein hydrolysate combined with Levodopa and Benserazide in treatment of patients with Parkinson’s disease

目的:观察脑蛋白水解物联合多巴丝肼治疗帕金森病患者的效果。方法:选取2018年3月至2022年8月郑州市第三人民医院收治的104例帕金森病患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各52例。对照组采用多巴丝肼片治疗,观察组在对照组基础上联合脑蛋白水解物治疗,比较两组治疗前后帕金森病综合评分量表(UPDRS)评分、神经功能相关标志物[脑源性神经营养因子(BDNF)、中枢神经特异性蛋白(S100β)、神经元特异性烯醇化酶(NSE)]水平、平衡功能[Berg平衡量表(BBS)]评分、功能性步行能力及预测跌倒风险[“起立-行走”计时测试(TUGT)]和不良反应发生率。结果:治疗后,两组精神行为和情绪、日常生活和能力、运动功能等UPDRS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组BDNF水平均高于治疗前,且观察组高于对照组,两组S100β、NSE水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组BBS评分均高于治疗前,且观察组高于对照组,两组TUGT时间均短于治疗前,且观察组短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:脑蛋白水解物联合多巴丝肼片治疗帕金森病患者可降低UPDRS评分,缩短TUGT时间,改善神经功能相关标志物水平,提高BBS评分,其效果优于单纯多巴丝肼片治疗。

Objective:To observe effects of Cerebroprotein hydrolysate combined with Levodopa and Benserazide in treatment of patients with Parkinson’s disease.Methods:A prospective study was conducted on 104 patients with Parkinson’s disease admitted to the Third People’s Hospital of Zhengzhou from March 2018 to August 2022.They were divided into control group and observation group according to the random number table method,52 cases in each group.The control group was treated with Levodopa and Benserazide tablets,while the observation group was treated with Cerebroprotein hydrolysate on the basis of that of the control group.The unified Parkinson’s disease rating scale(UPDRS)score,the neurological function related marker levels[brain-derived neurotrophic factor(BDNF),central nervous specific protein(S100β),neuron-specific enolase(NSE)],the balance function[Berg balance scale(BBS)]score,the functional walking ability and the predictive fall risk[timed up-and-go test(TUGT)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the UPDRS scores of mental behavior and emotion,daily life and ability,and motor function in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of BDNF in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of serum S100βand NSE in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the difference was statistically significant(P<0.05).The BBS scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the TUGT time of the two groups was shorter than that before the treatment,and that in the observation group was shorter than that in the control group;and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Cerebroprotein hydrolysate combined with Levodopa and Benserazide tablets in the treatment of the patients with Parkinson’s disease can reduce the UPDRS scores and the TUGT levels,improve the levels of neurological function-related markers,and improve the BBS scores.Moreover,it is superior to single Levodopa and Benserazide tablets treatment.